Compare ATLO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | OABI |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 237.4M |
| IPO Year | 2001 | N/A |
| Metric | ATLO | OABI |
|---|---|---|
| Price | $28.76 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 56.4K | ★ 712.9K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | $75.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $1.22 |
| 52 Week High | $29.71 | $2.61 |
| Indicator | ATLO | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 86.31 |
| Support Level | $27.55 | $1.43 |
| Resistance Level | $29.42 | N/A |
| Average True Range (ATR) | 0.63 | 0.16 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 73.44 | 93.84 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.